Economic analysis of a screening program for diabetes mellitus in Brazil;Análise econômica de programa para rastreamento do diabetes mellitus no Brasil

Revista de Saude Publica

Volumn 39, Issue 3, 2005, Pages 452-460

  Georg, Alvaro E ^a   Duncan, Bruce B ^a   Toscano, Cristiana M ^a   Schmidt, Maria Inês ^a   Mengue, Sotero ^a   Duarte, Cláudio ^b   Polanczyk, Carísi A ^a,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Cost benefit analysis; Diabetes mellitus, diagnosis; Diabetes mellitus, economy; Diabetes mellitus, prevention and control; Health promotion

Indexed keywords

GLUCOSE;

ADULT; ARTICLE; BRAZIL; COMMUNITY CARE; DIABETES MELLITUS; DIAGNOSTIC TEST; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; NONBIOLOGICAL MODEL; PREVALENCE; SCREENING; SENSITIVITY ANALYSIS;

EID: 23944484661     PISSN: 00348910     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0034-89102005000300017     Document Type: Article

References (25)

1. American Diabetes Association. Screening for diabetes. Diabetes Care 2002;25 Suppl 1:S21-4.
2. Barbosa RB, Barceló A, Machado CA. Campanha nacional de detecção de casos suspeitos de diabetes mellitus no Brasil: relatório preliminar. Rev Panam Salud Publica 2001; 10:324-7.
3. Bortheiry AL, Malerbi DA, Franco LJ. The ROC curve in the evaluation of fasting capillary blood glucose as a screening test for diabetes and IGT. Diabetes Care 1994;17:1269-72.
4. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998;280:1757-63.
5. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. BMJ 1998;317:371-5.
6. DECODE Study Group; on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;397:405-11.
7. Engelgau MM, Thompson TJ, Aubert RE, Herman WH. Screening for NIDDM in nonpregnant adults. Diabetes Care 1995;18:1606-18.
8. Gray A, Raikou M, McGuire A, Fenn P, Stevens R. Cull C et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomized controlled trial (UKPDS 41). BMJ 2000;320:1373-8.
9. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992;15:815-9.
10. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Diabetes Care 1998;21:1414-31.
11. Knowler WC, Barrett-Connor E, Fowler SE, Hamnan RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformina. N Engl J Med 2002;346:393-403.
12. Lee DS, Remington R, Madagame J, Blustein J. A cost analysis of community screening for diabetes in the central Wisconsin Medicare population. WMJ 2000;99:39-43.
13. Lotufo PA. Premature mortality from heart diseases in Brazil. A comparison with other countries. Arq Brasil Cardiol 1998; 5:321-5.
14. Malerbi DA, Franco LJ. Multicenter study of the prevalence of diabetes mellitus and impaired glucose tolerance in the urban Brazilian population aged 30-69 yr. Diabetes Care 1992;15:1509-16.
15. Ministério da Saúde/Organização Pan-Americana da Saúde. Avaliação do piano de reorganização da atenção à hipertensão arterial e ao diabetes mellitus no Brasil. Brasília (DF): Ministério da Saúde; 2004. p. 64.
16. Narayan KMV, Gregg EW, Fagot-Campagna A, Engelgau MM, Vinicor F. Diabetes- a common, growing, serious, costly, and potentially preventable public health problem. Diabetes Res Clin Pract 2000;50:S77-S84.
17. Blamey RW, Wilson ARM, Patnick J. ABC of breast diseases: screening for breast cancer. BMJ 2000;321:689-93.
18. Ministério da Saúde. Secretaria de Políticas Públicas. Plano de reorganização da atenção à hipertensão arterial e ao diabetes mellitus: fase de detecção de casos suspeitos de DM. Rev Saúde Pública 2001;35:490-3.
19. Ministério da Saúde. Secretaria de Políticas Públicas. Plano de reorganização da atenção à hipertensão arterial e ao diabetes mellitus. Rev Saúde Pública 2001;35:585-8.
20. The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-51.
21. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
22. UK National Screening Committee. The criteria for appraising the viability, effectiveness and appropriateness of a screening programme. London: Health Departments of the United Kingdom; 1998. Available from: URL: http://www.nsc.nhs.uk/pdfs/criteria.pdf [2002 Mai 22]
23. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
24. Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo I, Sakai M et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract 2000;48:201-10.
25. Wareham NJ, Griffin SJ. Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. BMJ 2001;322:986-8.